- TLC is listed on the Nasdaq Global Market (symbol: TLC)
- TLC reports positive top-line data from phase II clinical trial of TLC599 in knee osteoarthritis pain
- Doses first patients in phase I/II trial of TLC590 for postsurgical pain management
- TLC ranks Top 5% again in Corporate Governance Evaluations
- TLC178 is designated by the US FDA as an orphan drug for the treatment of soft tissue sarcoma and a rare pediatric disease in the treatment of rhabdomyosarcoma.